When was Rivermark founded?

Rivermark was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Rivermark located?

Rivermark is headquartered in Milwaukee, United States.

How many employees does Rivermark have?

As of Jun 30, 2026, the latest employee count at Rivermark is 18.

Is Rivermark a funded company?

Rivermark is a funded company, having raised a total of $54.2M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 20, 2023.

When was the latest funding round of Rivermark?

Rivermark's latest funding was a $***** Series D round on May 13, 2026, with participation from 1 investor.

Where does Rivermark rank among its competitors?

Rivermark ranks 2nd amongst 6 active competitors, of which 4 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Butterfly Medical, which secured $21M in May, 2026.

Who are the top competitors of Rivermark?

Rivermark's top competitors include Butterfly Medical, ProVerum Medical and Zenflow. Among them, Butterfly Medical secured the most recent funding round in May, 2026.

Rivermark - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of medical device for treatment of benign prostatic hyperplasia. It offers minimally invasive device FloStent which consist of a nitinol stent that holds the prostatic urethra open to restore normal urinary function.

Website: www.rivermarkmedical.com/
Email ID: *****@rivermarkmedical.com

Key Metrics

Founded Year

2021

Location

Milwaukee, United States

Stage

Series D

Total Funding

$54.2M in 3 rounds

Latest Funding Round

Series D, May 13, 2026, $*****

Investors

American Century Investments & 6 more

Ranked

2^nd among 6 active competitors

Employee Count

18 as on Jun 30, 2026

Similar Companies

Butterfly Medical & 4 more

View Rivermark's full profile

Rivermark is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Rivermark Medical, Inc. CIN: 872191689 , United States, Active		-	5 (As on Dec 31, 2024)	-

Rivermark has raised a total funding of $54.2M over 3 rounds. Its first funding round was on Jul 20, 2023. Its latest funding round was a Series D round on May 13, 2026 for $*****. 1 investor participated in its latest round. Rivermark has 7 institutional investors.

Here is the list of recent funding rounds of Rivermark:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2026	5360235	Series D	1985408	2770164	2603276	4117796
Sep 27, 2024	8690765	Series C	7322583	4570467	6822012	Venture Investors & 4 more
Jul 20, 2023	7388816	Series A	9211909	4398179	5295439	1292597

Access funding benchmarks and valuations. Sign up today!

View details of Rivermark's funding rounds and investors

The founders of Rivermark is Andy Doraiswamy.

Here are the details of Rivermark's key team members:

Andy Doraiswamy: Co-Founder & Chairman of Rivermark and founder of 2 other companies, Koya Medical and Koya.
Contact Info: 3 email addresses

View details of Rivermark's Founder profiles and Board Members

Rivermark's employee count trend

Rivermark has 18 employees as of Jun 26. Here is Rivermark's employee count trend over the years:

Uncover Rivermark's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rivermark include Butterfly Medical, ProVerum Medical and Zenflow. Here is the list of Top 10 competitors of Rivermark, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Butterfly Medical 2014, Yokneam Illit (Israel), Acquired	Developer of an implantable device for the treatment of benign prostatic hyperplasia (BPH)	$30M	New Rhein, MedVenture Partners & 11 others	58/100
2nd	Rivermark 2021, Milwaukee (United States), Series D	Developer of medical device for treatment of benign prostatic hyperplasia	$54.2M	Andera Partners, American Century Investments ... & 5 others	60/100
3rd	ProVerum Medical 2015, Dublin (Ireland), Series B	Developer of a minimally-invasive medical device for benign prostatic hyperplasia	$118M	Gilde Healthcare, MVM & 15 others	58/100
4th	Zenflow 2014, Palo Alto (United States), Series C	Developer of device to treat urinary obstruction related to BPH	$79.5M	Invus, F-Prime Capital & 22 others	56/100
5th	Tiumed 2016, Minneapolis (United States), Seed	Provider of medical technology solutions focused on developing advanced surgical systems for urology procedures	$766K	-	27/100
6th	Urologix 1991, Minneapolis (United States), Public	BPH therapy innovation leader, providing minimally invasive treatment options	-	InterWest Partners	26/100